Role of Shatyadi yoga in the management of Tamak shwasa (Bronchial Asthma)

Extracellular vesicles (EVs) are circulating vesicles secreted by various cell types. EVs are classified into three groups according to size, structural components, and generation process of vesicles: exosomes, microvesicles, and apoptotic bodies. Recently, EVs have been considered to be crucial for cell-to-cell communications and homeostasis because they contain intracellular proteins and nucleic acids. Epithelial cells from mice suffering from bronchial asthma (BA) secrete more EVs and suppress inflammation-induced EV production. Moreover, microarray analyses of bronchoalveolar lavage fluid have revealed that several microRNAs are useful novel biomarkers of BA. Mesenchymal stromal cell-derived EVs are possible candidates of novel BA therapy. In this review, we highlight the biologic roles of EVs in BA and review novel EV-targeted therapy to help understanding by clinicians and biologists.

Download Full-text

Role of anti-oxidants in the treatment of bronchial asthma

Drug Discovery Today Therapeutic Strategies ◽

10.1016/j.ddstr.2006.09.010 ◽

2006 ◽

Vol 3 (3) ◽

pp. 293-298

Author(s):

Graziano Riccioni ◽

Barbara Mancini ◽

Tonino Bucciarelli ◽

Carmine di Ilio ◽

Nicolantonio D’Orazio

Keyword(s):

Bronchial Asthma

Download Full-text

The role of pulmonary hypertension in the pathogenesis of bronchial asthma

Medical Hypotheses ◽

10.1016/0306-9877(90)90076-q ◽

1990 ◽

Vol 33 (1) ◽

pp. 7-9 ◽

Cited By ~ 3

Author(s):

V. Rosival

Keyword(s):

Pulmonary Hypertension ◽

Bronchial Asthma

Download Full-text

The Role of the Pulmonary Function Laboratory in Patients with Bronchial Asthma

Bronchial Asthma ◽

10.1007/978-1-59259-127-5_4 ◽

2001 ◽

pp. 95-118

Author(s):

Richard E. Kanner ◽

Theodore G. Liou

Keyword(s):

Pulmonary Function ◽

Bronchial Asthma

Download Full-text

Severe eosinophilic bronchial asthma: new therapeutic options

Medical Council ◽

10.21518/2079-701x-2018-15-44-52 ◽

2018 ◽

pp. 44-52 ◽

Cited By ~ 2

Author(s):

N. M. Nenasheva

Keyword(s):

Monoclonal Antibodies ◽

Severe Asthma ◽

Bronchial Asthma ◽

Biological Agents ◽

Therapeutic Options ◽

Clinical Use ◽

Eosinophilic Asthma ◽

Interleukin 5 ◽

Severe Eosinophilic Asthma

Eosinophilic asthma is a common phenotype of severe asthma, occurring in at least half of patients. In recent years, there have been significant changes in the approaches to the treatment of severe bronchial asthma and, above all, eosinophilic asthma. The article discusses the role of eosinophils in the pathogenesis of severe asthma, the detection of the phenotype of severe eosinophilic asthma, and modern approaches to targeting severe asthma with an eosinophilic phenotype using biological agents. A special emphasis is placed on preparations of monoclonal antibodies to interleukin-5, in particular, mepolizumab, recently approved for clinical use in our country.

Download Full-text